Trial Profile

A phase 3 study of duvakitug for the treatment of ulcerative colitis (UC) and Crohn's disease (CD)

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 20 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Duvakitug (Primary)
Indications Crohn's disease; Ulcerative colitis
Focus Therapeutic Use

Most Recent Events

30 Jul 2025 According to a Teva Pharmaceutical Industries media release, company announced the start of this trial in in Q4 2025.
18 Dec 2024 New trial record
17 Dec 2024 According to a Teva Pharmaceutical Industries media release, company's plan to initiate Phase 3 development in IBD, after pending regulatory discussions.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com